Notice Type
Departmental
Notice Title

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Adiramedica Desloratadine
Active Ingredient: Desloratadine 2.5mg/5mL
Dosage Form: Syrup
New Zealand Sponsor: AdiraMedica Pty Limited
Manufacturer: Gracure Pharmaceuticals Limited, Bhiwadi, India
   
Product: Cabometyx
Active Ingredient: Cabozantinib s-malate 25.34mg equivalent to cabozantinib 20mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Patheon Inc, Mississauga, Canada
   
Product: Cabometyx
Active Ingredient: Cabozantinib s-malate 50.69mg equivalent to cabozantinib 40mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Patheon Inc, Mississauga, Canada
   
Product: Cabometyx
Active Ingredient: Cabozantinib s-malate 76.03mg equivalent to cabozantinib 60mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Patheon Inc, Mississauga, Canada
   
Product: Desloratadine Hayfever & Allergy Relief
Active Ingredient: Desloratadine 2.5mg/5mL
Dosage Form: Syrup
New Zealand Sponsor: AdiraMedica Pty Limited
Manufacturer: Gracure Pharmaceuticals Limited, Bhiwadi, India
   
Product: Emgality (Prefilled Pen)
Active Ingredient: Galcanezumab 120mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Eli Lilly and Co Inc, Indiana, United States of America
   
Product: Emgality (Prefilled Syringe)
Active Ingredient: Galcanezumab 120mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Eli Lilly and Co Inc, Indiana, United States of America
   
Product: Fycompa
Active Ingredient: Perampanel hemisesquihydrate 2.1mg equivalent to perampanel 2mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Eisai New Zealand Limited
Manufacturers: Eisai Co Limited, Kakamigahara-shi, Japan
Eisai Manufacturing Limited, Hatfield, United Kingdom
   
Product: Fycompa
Active Ingredient: Perampanel hemisesquihydrate 4.2mg equivalent to perampanel 4mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Eisai New Zealand Limited
Manufacturers: Eisai Co Limited, Kakamigahara-shi, Japan
Eisai Manufacturing Limited, Hatfield, United Kingdom
   
Product: Fycompa
Active Ingredient: Perampanel hemisesquihydrate 6.2mg equivalent to perampanel 6mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Eisai New Zealand Limited
Manufacturers: Eisai Co Limited, Kakamigahara-shi, Japan
Eisai Manufacturing Limited, Hatfield, United Kingdom
   
Product: Fycompa
Active Ingredient: Perampanel hemisesquihydrate 8.3mg equivalent to perampanel 8mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Eisai New Zealand Limited
Manufacturers: Eisai Co Limited, Kakamigahara-shi, Japan
Eisai Manufacturing Limited, Hatfield, United Kingdom
   
Product: Fycompa
Active Ingredient: Perampanel hemisesquihydrate 10.4mg equivalent to perampanel 10mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Eisai New Zealand Limited
Manufacturers: Eisai Co Limited, Kakamigahara-shi, Japan
Eisai Manufacturing Limited, Hatfield, United Kingdom
   
Product: Fycompa
Active Ingredient: Perampanel hemisesquihydrate 12.5mg equivalent to perampanel 12mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Eisai New Zealand Limited
Manufacturers: Eisai Co Limited, Kakamigahara-shi, Japan
Eisai Manufacturing Limited, Hatfield, United Kingdom
   
Product: Paracetamol/Diphenhydramine
Active Ingredients: Diphenhydramine hydrochloride 25mg
Paracetamol 500mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Neo Health (NZ) Limited
Manufacturer: Titan Laboratories Pvt Limited, Mahad, India


Dated this 28th day of August 2020.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).